Laboratory of Lymphocyte Signaling and Oncoproteome

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL)

Staber, Philipp B.Herling, MarcoBellido, MarJacobsen, Eric D.Davids, Matthew S.Kadia, Tapan MahendraShustov, AndreiTournilhac, OlivierBachy, EmmanuelZaja, FrancescoPorkka, KimmoHoermann, GregorSimonitsch, IngridHaferlach, ClaudiaKubicek, StefanMayerhoefer, MariusHopfinger, GeorgJaeger, UlrichDearden, Claire
Blood July, 2019doi: 10.1182/blood.2019000402ISSN: 1528-0020

T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of T-PLL patients it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG)set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL and will thus support clinical decision making as well as the approval of new therapeutics by healthcare authorities.

Full text


Future therapies in T-PLL and T-LGL

Future therapies in T-PLL and T-LGL

June 7, 2021

New perspective on future targeted therapy approaches published.

New article accepted for publication

New article accepted for publication

August 30, 2020

Our work on T-PLL cells resembling the phenotype of activated memory-type effector T-cells has been accepted in Blood

Alkylating deacetylase inhibitor tinostamustine in T-PLL

March 11, 2020

New letter evaluating the effects of EDO-S101/tinostamustine published in Leukemia.

Advances and Perspectives in the Treatment of T-PLL

Advances and Perspectives in the Treatment of T-PLL

February 25, 2020

New review on current and future strategies in treating T-PLL published in Current Hematologic Malignancy Reports